Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian …

IB Vergote, F Joly, D Katsaros, C Coens, A Reinthaller… - 2012 - ascopubs.org
LBA5000 Background: The epidermal growth factor receptor (EGFR) has been found to be
overexpressed in 55-98% of advanced epithelial ovarian cancer. This trial evaluated the …
被引用次数：30 相关文章

[引用][C] Randomized phase III Study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for …

V IB - J Clin Oncol, 2012 - cir.nii.ac.jp
Randomized phase III Study of erlotinib versus observation in patients with no evidence of
disease progression after first-line platin-based chemotherapy for ovarian carcinoma : a GCIG …

[引用][C] Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for …

IB Vergote, F Joly, D Katsaros, C Coens… - Journal of Clinical …, 2012 - ascopubs.org
LBA5000 The full, final text of this abstract will be available at abstract. asco. org at 12: 01
AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online …